Study design and participants
unresectable HCC, tumor, HCC, Tumors
TUMORS, DISEASE PROGRESSION, TUMOR
This single-arm, open-label trial for patients with unresectable HCC was conducted at 3 medical centers in Taiwan (ClinicalTrials.gov identifier NCT03893695). Key eligibility criteria included the following: age ≥ 20 years; histologically or cytologically confirmed unresectable HCC that was refractory or not amenable to locoregional therapy; disease progression or intolerance after first-line systemic treatment; at least one measurable tumor lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 [